Company / Operating Income per Share
Kymera Therapeutics, Inc. Operating Income per Share History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$5.38
FY2025
5-year range
-$5.38 / -$0.95
FY2021-FY2025
Trend
-14.4%
vs FY2024
Sector context
#172 of 201
Health Care
What the data says
Kymera Therapeutics, Inc.'s operating income per share of $-5.38 is lower than 86% of companies in the Health Care sector (FY2025). Operating Income per Share has declined for 4 consecutive years, from $-0.95 in FY2021 to $-5.38 in FY2025.
Based on SEC 10-K filings.
-5.38 in FY2025.
Declined from $-3.45 to $-5.38 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 201This company -$5.38 Sector average -$3.23
▼
-66.5% below sector average
Key checks
Key Insights
- Kymera Therapeutics, Inc.'s operating income per share has declined for 4 consecutive years.
- In FY2025, operating income per share decreased 14.4% year-over-year.
- Ranks #172 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 3.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$5.38 | -14.4% |
| FY2024 | -$4.71 | -36.5% |
| FY2023 | -$3.45 | -10.2% |
| FY2022 | -$3.13 | -229.8% |
| FY2021 | -$0.95 | +95.7% |
| FY2020 | -$21.87 | +12.0% |
| FY2019 | -$24.85 | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 30, 2026